Send to

Choose Destination
J Immunother. 2014 Jan;37(1):51-4. doi: 10.1097/CJI.0000000000000006.

Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

Author information

*Oncologie, Besançon Cedex §CIC-BT506, CHRU †INSERM, UMR1098 ‡UMR1098, Université de Franche-Comté ∥EFS Bourgogne Franche-Comté ¶Laboratoire de Pharmacologie Clinique et Toxicologie, Besançon, France.


Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. Besides, mammalian target of rapamycin inhibition has the ability to modulate T-lymphocyte homeostasis. Here, we report the case of a metastatic renal cell carcinoma patient treated with everolimus who presented unexpected prolonged tumor response. The monitoring of immune responses showed strong antitumor T-cell activation at the time of disease control, whereas a profound immunosuppression occurred when tumor progressed. Thus, a change of immune functions is associated with everolimus treatment. Our observation suggests that everolimus could shape immune responses, which in turn could contribute to its efficacy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center